

Amendments to the Specification:

Please add the following title and paragraph as a separate page following the claims:

ABSTRACT

A method is disclosed of determining the presence of catalytic anti-Factor VIII allo-antibodies capable of degrading Factor VIII in a mammal, and of characterising the cleavage sites in said Factor VIII molecule by said catalytic anti-Factor VIII allo-antibodies. It also relates to an anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor; and to a pharmaceutical composition comprising said catalytic anti-Factor VIII allo-antibodies which are capable of degrading Factor VIII and which originate from said method of determination; and further to a pharmaceutical composition comprising said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor. Finally, the present invention relates to the application in therapeutics of said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor, of a pharmaceutical composition comprising said catalytic anti-Factor VIII allo-antibodies which are capable of degrading Factor VIII and which originate from said method of determination, and of a pharmaceutical composition comprising said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor.

Please amend the specification as follows:

On page 5, please replace the paragraph beginning on line 23 with the following:

SEQ. ID N° 1: Ser Val Ala Lys Lys His Pro:
1 5

On page 5, please replace the paragraph beginning on line 27 with the following:

SEQ. ID N° 2: Asp Glu Asp Glu Asn Gln Ser; and
1 5

On page 5, please replace the paragraph beginning on line 31 with the following:

SEQ. ID N° 3: Asp Gln Arg Gln Gly Ala Glu.
1 5

On page 7, please replace the paragraph beginning on line 2 (the first line of text on page 7) with the following:

SEQ. ID N° 1: Ser Val Ala Lys Lys His Pro:
1 5

On page 7, please replace the paragraph beginning on line 6 with the following:

SEQ. ID N° 2: Asp Glu Asp Glu Asn Gln Ser; or
1 5

On page 7, please replace the paragraph beginning on line 10 with the following:

SEQ. ID N° 3: Asp Gln Arg Gln Gly Ala Glu.
1 5

On page 15, please replace the paragraph beginning on line 19 with the following:

Figure 3 Figures 3 A-D: Dose- and time-dependency of proteolysis of [¹²⁵I]-Factor VIII by affinity-purified anti-Factor VIII antibodies of haemophilia A patients with inhibitor.

On page 15, please replace the paragraph beginning on line 23 with the following:

The kinetics of the hydrolysis of Factor VIII by anti-Factor VIII allo-antibodies of patients Bor (Figs. 3A and 3C) and Wal (Figs. 3B and 3D). The rate of hydrolysis of [I-125]-labelled Factor VIII by anti-Factor IgG of patient Wal was faster than that exhibited by anti-Factor VIII IgG of patient Bor, suggesting either that catalytic antibodies of the patients exhibit different kinetic properties, or, alternatively, that the proportion of catalytic antibodies among the anti-Factor VIII antibodies differ between the patients.

On page 20, please replace the table with the following table:

Appl. No. 10/031,938

Response to Office Action mailed on November 18, 2005

Amino Acid Sequence	Cleavage Site
<u>SEQ. ID N° 1:</u> Ser Val Ala Lys Lys His Pro 1 5 (SVAKKHP)	Arg ³⁷² – Ser ³⁷³ (R ³⁷² – S ³⁷³)
<u>SEQ. ID N° 2:</u> Asp Gln Arg Gln Gly Ala Glu 1 5 (DQRQGAE)	Glu ¹⁷⁹⁴ – Asp ¹⁷⁹⁵ (E ¹⁷⁹⁴ – D ¹⁷⁹⁵)
<u>SEQ. ID N° 3:</u> Asp Glu Asp Glu Asn Gln Sr 1 5 (DEDENQS)	Tyr ¹⁶⁸⁰ – Asp ¹⁶⁸¹ (Y ¹⁶⁸⁰ – D ¹⁶⁸¹)